Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment

Sarah L Anderson PharmD, Joel C Marrs PharmD

Abstract

Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-inclass angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN.

Article Details

Article Type

Review

DOI

10.7573/dic.212542

Publication Dates

Accepted: ; Published: .

Citation

Anderson SL, Marrs JC. Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. Drugs in Context 2018; 7: 212542. DOI: 10.7573/dic.212542

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.